Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
Tomoko KobayashiShintaro IwamaAyana YamagamiYoshinori YasudaTakayuki OkujiMasaaki ItoXin ZhouMasahiko AndoTakeshi OnoueTakashi MiyataMariko SugiyamaDaisuke HagiwaraHidetaka SugaRyoichi BannoTetsunari HaseMasahiro MoriseTakanori ItoToyone KikumoriMegumi InoueYuichi AndoNorikazu MasudaHiroki KawashimaNaozumi HashimotoHiroshi ArimaPublished in: The Journal of clinical endocrinology and metabolism (2022)
The results of this real-world study suggest that the risk of thyroid dysfunction induced by PD-L1-Abs can be predicted by the TSH level at baseline, TgAb positivity at baseline, and prior treatment with RAM or multi-TKIs.
Keyphrases